OHSU Knight Cancer Institute: Multiple Myeloma trials

The registry lists 13 Multiple Myeloma studies with OHSU Knight Cancer Institute as lead sponsor. 1 are open to participants now and 3 have results posted.

Phase 1 4Phase 2 5Phase 3 1No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T TreatmentRecruitingNCT06784167
• Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving ChemotherapyTerminatedNCT04465760Phase 2Results posted
• Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic CancerTerminatedNCT00281879Phase 2Results posted
• Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00245037Phase 1/2Results posted
• Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04850599Phase 2
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple MyelomaCompletedNCT02504359Phase 1
• Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01689987Phase 1
• Blood Samples From Patients on a Clinical Trial to CINV During HSCTTerminatedNCT00900068
• Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or MyelomaCompletedNCT00900055
• Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell TransplantTerminatedNCT00324324Phase 3
• G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic DisordersTerminatedNCT00253552Not applicable
• Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00227682Phase 2